These findings suggest that PSMA PET imaging outperforms lpWGS-based ctDNA analysis in detecting prostate cancer across the whole spectrum of disease, with both modalities being independently highly prognostic for survival outcomes. This evidence concerns the gene FOLH1 and prostate cancer.